AN ACT Relating to anaphylaxis medications in schools;
SB 5240 updates Washington law on anaphylaxis preparedness in schools. It allows school districts and private schools to maintain supplies of epinephrine, including epinephrine auto-injectors, in designated school locations based on enrollment, and authorizes licensed health professionals with prescribing authority to prescribe school-stock epinephrine in the name of the district or school. The bill also clarifies when school nurses and trained personnel may use school-supplied or available epinephrine to respond to a potentially life-threatening allergic reaction, including when a student does not have a personal prescription on file.
The bill expands where and when epinephrine may be used, expressly covering school property, playgrounds, buses, field trips, and sanctioned excursions. It also provides liability protections for prescribers and pharmacists absent conscious disregard for safety, and protects school employees and districts from liability when epinephrine is administered in substantial compliance with a student prescription, standing order, or aligned school policy. In addition, employees who do not want epinephrine auto-injector use to be part of their job duties may file a written refusal without adverse employment consequences.
Beyond medication access, SB 5240 directs the Office of the Superintendent of Public Instruction, in consultation with the Department of Health, to develop anaphylaxis policy guidelines for schools. Those guidelines must address treatment plans, staff training, individualized emergency health care plans, communication procedures, and strategies to reduce allergen exposure. The bill also requires reporting to the Legislature on implementation of existing food allergy guidance and on recommendations for effective statewide implementation.
The overall sentiment around the bill appears strongly supportive and noncontroversial. It passed the Senate committee and Senate floor unanimously, and later received unanimous support in a House education committee vote with amendments. The voting history suggests broad agreement that schools should be better equipped to prevent and respond to anaphylaxis emergencies.
The main points of potential contention are operational rather than ideological: how much responsibility schools should bear for stocking and administering epinephrine, how training and standing protocols should be implemented, and how employee refusal rights should be balanced against school safety needs. The bill also raises practical questions about reimbursement for used medication and the scope of liability protections, but the available record shows no recorded opposition in committee or floor votes.
SB 5240 amends Washington statutes governing school health and emergency response by expanding school authority to stock and administer epinephrine and epinephrine auto-injectors, and by creating a more detailed statewide framework for anaphylaxis preparedness. It affects school districts, private schools, charter schools, state-tribal compact schools, school nurses, trained school personnel, prescribing health professionals, pharmacists, and school employees. The bill also requires OSPI and DOH to issue policy guidance and mandates district-level policies aligned with those guidelines.
The bill’s reception was overwhelmingly positive. It advanced out of the Senate committee 9-0 and passed the Senate floor 49-0, with another unanimous 19-0 vote in the House Education Committee. The voting pattern indicates broad bipartisan support for improving school readiness to respond to severe allergic reactions and for clarifying school authority and protections around epinephrine use.
No major partisan or policy opposition is reflected in the available votes or transcripts. The most notable issues are implementation details: stocking and maintaining epinephrine supplies, training school staff, deciding who may administer medication in emergencies, and defining liability protections when school personnel act under standing orders or school policy. Employee refusal provisions could also be a point of concern for some stakeholders, but the bill’s record shows no organized resistance in the materials provided.